Moderna eyes $500M secondary offering on upbeat coronavirus vaccine update — almost ready for the clinic
Among the army of biotechs that threw themselves into the gold rush for 2019-nCoV vaccines or therapies, Moderna emerged as one of the most legitimate contenders: The NIH had signed it on as a partner, demonstrating confidence in its messenger RNA platform to produce a vaccine rapidly.
That has given the Cambridge, MA-based biotech a nice bump on its unicorn valuation. And CEO Stéphane Bancel is seizing it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.